Movatterモバイル変換

[0]ホーム

Jump to content

EPHA7

Edit links

From Wikipedia, the free encyclopedia

Protein-coding gene in the species Homo sapiens

EPHA7

Available structures

PDB

Ortholog search:PDBe RCSB

List of PDB id codes
2REI,3DKO,3H8M,3NRU

Identifiers

Aliases

EPHA7, EHK-3, EHK3, EK11, HEK11, EPH receptor A7

External IDs

OMIM:602190;MGI:95276;HomoloGene:20935;GeneCards:EPHA7;OMA:EPHA7 - orthologs

Gene location (Human)

Chr.	Chromosome 6 (human)^[1]

Band	6q16.1	Start	93,240,020bp^[1]
Band	6q16.1	End	93,419,559bp^[1]

Gene location (Mouse)

Chr.	Chromosome 4 (mouse)^[2]

Band	4 A4\|4 12.42 cM	Start	28,813,131bp^[2]
Band	4 A4\|4 12.42 cM	End	28,967,499bp^[2]

RNA expression pattern

Bgee

Human

Mouse (ortholog)

Top expressed in

endothelial cell

Brodmann area 23

middle temporal gyrus

muscle layer of sigmoid colon

ganglionic eminence

ventricular zone

caput epididymis

primary visual cortex

gastric mucosa

epithelium of colon

Top expressed in

vestibular membrane of cochlear duct

dentate gyrus

Region I of hippocampus proper

hippocampus proper

dentate gyrus of hippocampal formation granule cell

CA3 field

genital tubercle

atrioventricular valve

habenula

atrium

More reference expression data

BioGPS


More reference expression data

Gene ontology
Molecular function	transferase activity nucleotide binding protein kinase activity GPI-linked ephrin receptor activity ephrin receptor binding kinase activity protein binding transmembrane receptor protein tyrosine kinase activity protein tyrosine kinase activity ATP binding axon guidance receptor activity ephrin receptor activity chemorepellent activity receptor tyrosine kinase transmembrane signaling receptor activity transmembrane-ephrin receptor activity
Cellular component	integral component of membrane postsynaptic membrane membrane neuromuscular junction plasma membrane integral component of plasma membrane soma dendrite Schaffer collateral - CA1 synapse hippocampal mossy fiber to CA3 synapse glutamatergic synapse integral component of postsynaptic specialization membrane integral component of postsynaptic density membrane cytoplasm neuron projection receptor complex
Biological process	apoptotic process positive regulation of protein phosphorylation regulation of protein autophosphorylation phosphorylation transmembrane receptor protein tyrosine kinase signaling pathway ephrin receptor signaling pathway negative regulation of synapse assembly regulation of cysteine-type endopeptidase activity involved in apoptotic process nervous system development branching morphogenesis of a nerve multicellular organism development protein phosphorylation negative regulation of collateral sprouting positive regulation of neuron apoptotic process brain development nephric duct morphogenesis regulation of cell-cell adhesion regulation of ERK1 and ERK2 cascade positive regulation of apoptotic process peptidyl-tyrosine phosphorylation regulation of peptidyl-tyrosine phosphorylation retinal ganglion cell axon guidance negative chemotaxis regulation of postsynapse organization negative regulation of signal transduction cell differentiation negative regulation of apoptotic process positive regulation of ERK1 and ERK2 cascade axon guidance
Sources:Amigo /QuickGO

Orthologs

Species

Human

Mouse

Entrez


2045


13841

Ensembl


ENSG00000135333


ENSMUSG00000028289

UniProt


Q15375


Q61772

RefSeq (mRNA)


NM_001288629 NM_001288630 NM_004440


NM_001122889 NM_001290434 NM_010141

RefSeq (protein)

NP_001275558 NP_001275559 NP_004431 NP_001363394 NP_001363395
NP_001363396 NP_001363397 NP_001363398 NP_001363399 NP_001363400


NP_001116361 NP_001277363 NP_034271

Location (UCSC)

Chr 6: 93.24 – 93.42 Mb

Chr 4: 28.81 – 28.97 Mb

PubMed search

^[3]

^[4]

Wikidata

View/Edit Human

View/Edit Mouse

Ephrin type-A receptor 7 is aprotein that in humans is encoded by theEPHA7gene.^[5]^[6]

This gene belongs to theephrin receptor subfamily of theprotein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in thenervous system. Receptors in the EPH subfamily typically have a singlekinase domain and an extracellular region containing a Cys-rich domain and 2fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-Bligands.^[6]

References

[edit]

^^a ^b ^cGRCh38: Ensembl release 89: ENSG00000135333 –Ensembl, May 2017
^^a ^b ^cGRCm38: Ensembl release 89: ENSMUSG00000028289 –Ensembl, May 2017
^"Human PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
^Ephnomenclaturecommittee (Sep 1997)."Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee".Cell.90 (3):403–4.doi:10.1016/S0092-8674(00)80500-0.PMID 9267020.S2CID 26773768.
^^a ^b"Entrez Gene: EPHA7 EPH receptor A7".

Flanagan JG, Vanderhaeghen P (1998). "The ephrins and Eph receptors in neural development".Annu. Rev. Neurosci.21:309–45.doi:10.1146/annurev.neuro.21.1.309.PMID 9530499.
Zhou R (1998). "The Eph family receptors and ligands".Pharmacol. Ther.77 (3):151–81.doi:10.1016/S0163-7258(97)00112-5.PMID 9576626.
Holder N, Klein R (1999). "Eph receptors and ephrins: effectors of morphogenesis".Development.126 (10):2033–44.doi:10.1242/dev.126.10.2033.PMID 10207129.
Wilkinson DG (2000). "Eph receptors and ephrins: regulators of guidance and assembly".Int. Rev. Cytol. International Review of Cytology.196:177–244.doi:10.1016/S0074-7696(00)96005-4.ISBN 978-0-12-364600-2.PMID 10730216.
Xu Q, Mellitzer G, Wilkinson DG (2001)."Roles of Eph receptors and ephrins in segmental patterning".Philos. Trans. R. Soc. Lond. B Biol. Sci.355 (1399):993–1002.doi:10.1098/rstb.2000.0635.PMC 1692797.PMID 11128993.
Wilkinson DG (2001). "Multiple roles of EPH receptors and ephrins in neural development".Nat. Rev. Neurosci.2 (3):155–64.doi:10.1038/35058515.PMID 11256076.S2CID 205014301.
Fox GM, Holst PL, Chute HT, et al. (1995). "cDNA cloning and tissue distribution of five human EPH-like receptor protein-tyrosine kinases".Oncogene.10 (5):897–905.PMID 7898931.
Gale NW, Holland SJ, Valenzuela DM, et al. (1996)."Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis".Neuron.17 (1):9–19.doi:10.1016/S0896-6273(00)80276-7.PMID 8755474.S2CID 1075856.
Bonaldo MF, Lennon G, Soares MB (1997)."Normalization and subtraction: two approaches to facilitate gene discovery".Genome Res.6 (9):791–806.doi:10.1101/gr.6.9.791.PMID 8889548.
Ciossek T, Ullrich A (1997). "Identification of Elf-1 and B61 as high affinity ligands for the receptor tyrosine kinase MDK1".Oncogene.14 (1):35–43.doi:10.1038/sj.onc.1200800.PMID 9010230.S2CID 24727040.
Hock B, Böhme B, Karn T, et al. (1998)."PDZ-domain-mediated interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF6 depends on the kinase activity of the receptor".Proc. Natl. Acad. Sci. U.S.A.95 (17):9779–84.Bibcode:1998PNAS...95.9779H.doi:10.1073/pnas.95.17.9779.PMC 21413.PMID 9707552.
Bianchi LM, Liu H (1999)."Comparison of ephrin-A ligand and EphA receptor distribution in the developing inner ear".Anat. Rec.254 (1):127–34.doi:10.1002/(SICI)1097-0185(19990101)254:1<127::AID-AR16>3.0.CO;2-Q.PMID 9892426.
Janis LS, Cassidy RM, Kromer LF (1999)."Ephrin-A binding and EphA receptor expression delineate the matrix compartment of the striatum".J. Neurosci.19 (12):4962–71.doi:10.1523/JNEUROSCI.19-12-04962.1999.PMC 6782661.PMID 10366629.
Stubbs J, Palmer A, Vidovic M, Marotte LR (2000). "Graded expression of EphA3 in the retina and ephrin-A2 in the superior colliculus during initial development of coarse topography in the wallaby retinocollicular projection".Eur. J. Neurosci.12 (10):3626–36.doi:10.1046/j.1460-9568.2000.00251.x.PMID 11029633.S2CID 37988439.

Protein kinases:tyrosine kinases (EC 2.7.10)

Receptor tyrosine kinases (EC 2.7.10.1)

Growth factor receptors

EGF receptor family	EGFR ERBB2 ERBB3 ERBB4
Insulin receptor family	IGF1R INSR INSRR
PDGF receptor family	CSF1R FLT3 KIT PDGFR (PDGFRA PDGFRB)
FGF receptor family	FGFR1 FGFR2 FGFR3 FGFR4
VEGF receptors family	VEGFR1 VEGFR2 VEGFR3
HGF receptor family	MET RON
Trk receptor family	NTRK1 NTRK2 NTRK3

EPH receptor family

LTK receptor family

TIE receptor family

ROR receptor family

DDR receptor family

PTK7 receptor family

PTK7

RYK receptor family

MuSK receptor family

MUSK

ROS receptor family

ROS1

AATYK receptor family

AXL receptor family

RET receptor family

uncategorised

STYK1

Non-receptor tyrosine kinases (EC 2.7.10.2)

ABL family	ABL1 ARG
ACK family	ACK1 TNK1
CSK family	CSK MATK
FAK family	FAK PYK2
FES family	FES FER
FRK family	FRK BRK SRMS
JAK family	JAK1 JAK2 JAK3 TYK2
SRC-A family	SRC FGR FYN YES1
SRC-B family	BLK HCK LCK LYN
TEC family	TEC BMX BTK ITK TXK
SYK family	SYK ZAP70

v t e Enzymes
Activity	Active site Binding site Catalytic triad Oxyanion hole Enzyme promiscuity Diffusion-limited enzyme Cofactor Enzyme catalysis
Regulation	Allosteric regulation Cooperativity Enzyme inhibitor Enzyme activator
Classification	EC number Enzyme superfamily Enzyme family List of enzymes
Kinetics	Enzyme kinetics Eadie–Hofstee diagram Hanes–Woolf plot Lineweaver–Burk plot Michaelis–Menten kinetics
Types	EC1Oxidoreductases (list) EC2Transferases (list) EC3Hydrolases (list) EC4Lyases (list) EC5Isomerases (list) EC6Ligases (list) EC7Translocases (list)

Growth factor receptor modulators

Angiopoietin

Agonists:Angiopoietin 1
Angiopoietin 4

Antagonists:Angiopoietin 2
Angiopoietin 3

Kinase inhibitors:Altiratinib
CE-245677
Rebastinib

Antibodies:Evinacumab (against angiopoietin 3)
Nesvacumab (against angiopoietin 2)

CNTF

EGF (ErbB)

EGF (ErbB1/HER1)	Agonists:Amphiregulin Betacellulin EGF (urogastrone) Epigen Epiregulin Heparin-binding EGF-like growth factor (HB-EGF) Murodermin Nepidermin Transforming growth factor alpha (TGFα) Kinase inhibitors:Afatinib Agerafenib Brigatinib Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies:Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab
ErbB2/HER2	Agonists:Unknown/none Antibodies:Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab emtansine Kinase inhibitors:Afatinib Lapatinib Mubritinib Neratinib Tucatinib
ErbB3/HER3	Agonists:Neuregulins (heregulins) (1,2,6 (neuroglycan C)) Antibodies:Duligotumab Patritumab Seribantumab
ErbB4/HER4	Agonists:Betacellulin Epigen Heparin-binding EGF-like growth factor (HB-EGF) Neuregulins (heregulins) (1,2,3,4,5 (tomoregulin, TMEFF))

FGF

FGFR1	Agonists:Ersofermin FGF (1,2 (bFGF),3,4,5,6,8,10 (KGF2),20) Repifermin Selpercatinib Trafermin Velafermin
FGFR2	Agonists:Ersofermin FGF (1,2 (bFGF),3,4,5,6,7 (KGF),8,9,10 (KGF2),17,18,22) Palifermin Repifermin Selpercatinib Sprifermin Trafermin Antibodies:Aprutumab Aprutumab ixadotin Kinase inhibitors:Infigratinib
FGFR3	Agonists:Ersofermin FGF (1,2 (bFGF),4,8,9,18,23) Selpercatinib Sprifermin Trafermin Antibodies:Burosumab (against FGF23)
FGFR4	Agonists:Ersofermin FGF (1,2 (bFGF),4,6,8,9,19) Trafermin
Unsorted	Agonists:FGF15/19

HGF (c-Met)

Agonists:Fosgonimeton
Hepatocyte growth factor

Potentiators:Dihexa (PNB-0408)

IGF

IGF-1	Agonists:des(1-3)IGF-1 Insulin-like growth factor-1 (somatomedin C) IGF-1 LR3 Insulin-like growth factor-2 (somatomedin A) Insulin Mecasermin Mecasermin rinfabate Kinase inhibitors:BMS-754807 Linsitinib NVP-ADW742 NVP-AEW541 OSl-906 Antibodies:AVE-1642 Cixutumumab Dalotuzumab Figitumumab Ganitumab Robatumumab R1507 Teprotumumab Xentuzumab (against IGF-1 and IGF-2)
IGF-2	Agonists:Insulin-like growth factor-2 (somatomedin A) Antibodies:Dusigitumab Xentuzumab (against IGF-1 and IGF-2)
Others	Binding proteins:IGFBP (1,2,3,4,5,6,7) Cleavage products/derivatives with unknown target:Glypromate (GPE, (1-3)IGF-1) Trofinetide

LNGF (p75^NTR)

Antibodies:Against NGF:ABT-110 (PG110)
ASP-6294
Fasinumab
Frunevetmab
Fulranumab
MEDI-578
Ranevetmab
Tanezumab

Aptamers:Against NGF:RBM-004

Decoy receptors:LEVI-04 (p75^NTR-Fc)

PDGF

Agonists:Becaplermin
Platelet-derived growth factor (A,B,C,D)

RET (GFL)

GFRα1	Agonists:Glial cell line-derived neurotrophic factor (GDNF) Liatermin Kinase inhibitors:Vandetanib
GFRα2	Agonists:Neurturin (NRTN) Kinase inhibitors:Vandetanib
GFRα3	Agonists:Artemin (ARTN) Kinase inhibitors:Vandetanib
GFRα4	Agonists:Persephin (PSPN) Kinase inhibitors:Vandetanib
Unsorted	Kinase inhibitors:Agerafenib

SCF (c-Kit)

Agonists:Ancestim
Stem cell factor

TGFβ

Seehere instead.

Trk

TrkA	Agonists:Amitriptyline BNN-20 BNN-27 Cenegermin DHEA DHEA-S Gambogic amide NGF Tavilermide Antagonists:ALE-0540 Dexamethasone FX007 Testosterone Negative allosteric modulators:VM-902A Kinase inhibitors:Altiratinib AZD-6918 CE-245677 CH-7057288 DS-6051 Entrectinib GZ-389988 K252a Larotrectinib Lestaurtinib Milciclib ONO-4474 ONO-5390556 PLX-7486 Rebastinib SNA-120 (pegylated K252a)) Antibodies:Against TrkA:GBR-900;Against NGF:ABT-110 (PG110) ASP-6294 Fasinumab Frunevetmab Fulranumab MEDI-578 Ranevetmab Tanezumab Aptamers:Against NGF:RBM-004 Decoy receptors:ReN-1820 (TrkAd5)
TrkB	Agonists:3,7-DHF 3,7,8,2'-THF 4'-DMA-7,8-DHF 7,3'-DHF 7,8-DHF 7,8,2'-THF 7,8,3'-THF Amitriptyline BDNF BNN-20 Deoxygedunin Deprenyl Diosmetin DMAQ-B1 HIOC LM22A-4 N-Acetylserotonin NT-3 NT-4 Norwogonin (5,7,8-THF) R7 R13 TDP6 Antagonists:ANA-12 Cyclotraxin B Gossypetin (3,5,7,8,3',4'-HHF) Ligands:DHEA Kinase inhibitors:Altiratinib AZD-6918 CE-245677 CH-7057288 DS-6051 Entrectinib GZ-389988 K252a Larotrectinib Lestaurtinib ONO-4474 ONO-5390556 PLX-7486
TrkC	Agonists:BNN-20 DHEA NT-3 Kinase inhibitors:Altiratinib AZD-6918 CE-245677 CH-7057288 DS-6051 Entrectinib GZ-389988 K252a Larotrectinib Lestaurtinib ONO-4474 ONO-5390556 PLX-7486